IMTX IMTX
Company Profile ↓Company Overview
IMTX (IMTX) is a publicly traded company listed on with a market capitalization of $1.31B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $48.27M (-69.0% YoY); net profit $-196.45M.
- Trailing 12 Months Year-on-year growth — revenue -69.0%, earnings -1390.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -34.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -34.64% |
| 1 Year: | -69.03% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -1,390.89% |
Stock Price Performance
| 1 Year: | +47.81% |
| 6 Months: | -1.81% |
| 3 Months: | -10.78% |
| 1 Month: | -4.78% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)55.46 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -34.6% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 18.58M | 4.74M | 5.19M | 19.76M | 7.61M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 53.96M | 57.86M | 59.82M | 58.64M | 73.68M |
| Operating Income | -35.37M | -53.13M | -54.63M | -38.88M | -66.06M |
| EBITDA | -37.46M | -68.08M | -47.38M | -32.17M | -54.77M |
| Interest Expense | 249.00K | 244.00K | 231.00K | 222.00K | 212.00K |
| Pretax Income | -40.85M | -71.35M | -50.67M | -35.56M | -57.76M |
| Tax Provision | -994.00K | -1.00M | -127.00K | 134.00K | 52.00K |
| Net Income | -39.85M | -70.35M | -50.55M | -35.70M | -57.81M |
| Diluted EPS | -0.33 | -0.58 | -0.42 | - | -0.43 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 172.83M | 54.00M | 155.84M | 48.27M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 142.88M | 155.72M | 194.45M | 230.28M |
| Operating Income | - | 29.95M | -101.72M | -38.62M | -182.02M |
| EBITDA | - | 50.04M | -88.93M | 34.46M | -185.09M |
| Interest Expense | - | 1.04M | 831.00K | 886.00K | 946.00K |
| Pretax Income | - | 42.04M | -96.99M | 21.35M | -198.44M |
| Tax Provision | - | 14.33M | -2.35M | 6.13M | -1.99M |
| Net Income | - | 27.70M | -94.65M | 15.22M | -196.45M |
| Diluted EPS | - | 0.55 | -1.18 | 0.14 | -1.61 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 407.82M | 509.96M | 696.15M | 562.34M |
| Current Assets | - | 377.15M | 449.37M | 629.55M | 504.01M |
| Cash & Equivalents | - | 148.52M | 218.47M | 236.75M | 345.92M |
| Inventory | - | - | - | - | - |
| Receivables | - | 1.11M | 4.09M | 5.86M | 6.10M |
| Total Liabilities | - | 204.47M | 292.35M | 121.30M | 78.24M |
| Current Liabilities | - | 106.45M | 156.55M | 67.99M | 43.01M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 14.56M | 15.40M | 16.20M | 15.63M |
| Total Equity | - | 203.35M | 217.62M | 574.84M | 484.10M |
| Shares Outstanding | - | 76.67M | 84.66M | 121.55M | 134.07M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 100.13M | 18.23M | -158.03M | -176.63M |
| Investing Cash Flow | - | -209.79M | -31.39M | -152.39M | 204.79M |
| Financing Cash Flow | - | 123.71M | 84.52M | 319.68M | 97.35M |
| Capital Expenditure | - | -6.21M | -30.96M | -16.48M | -6.80M |
| Free Cash Flow | - | 93.92M | -12.73M | -174.51M | -183.43M |
| Net Change in Cash | - | 14.05M | 71.36M | 9.27M | 125.51M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | 17.3% | -188.4% | -24.8% | -377.1% |
| Net Margin % | - | 16.0% | -175.3% | 9.8% | -407.0% |
| ROE % | - | 13.6% | -43.5% | 2.6% | -40.6% |
| ROCE % | - | 9.9% | -28.8% | -6.1% | -35.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IMTX
Immatics (IMTX) Stock Looks Expensive After PRAME Platform Update And Cash Runway To 2028 - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxPRzZSWmJRZmNxNGhkUk92V1Nvek5hdzNWLUVBQTdONl9rYnhGdlN6N0tsbXlzTmFvZXI1bC1lczFHb0hGWVVHWnMwRFh1bGxLVW9ndTNrU19pWXlveHU1d3p2LWUzel9QeTZlb2pKN3BaaVBnUjdnbFoweEJZeUxlU1lRZlBVdXYtbVk3Q2…
IMTX Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5vTDBuRk8ydHlWZ2tVNHJIMTFaZGVRdlFXZ0w1b09uV1NMVmNyTlJDMndudzRaWWZYWl90SHVjR0dhaGNIU1dVWGlneXQ0OGVza2dTbloxakJ1LUFvdnI0a2RBdF9tQ1dZcnFEaWE4SnVxdUcwQUwwUUx3?oc=5" target="_blank">IMT…
Melanoma cell therapy targets 2027 debut as Immatics posts $66.5M Q1 loss - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQZno1cUJwM1dudTRVc3F1bHZBSWZJY2h0b3BXV3NqeUNCQUNrTVQ2dnNCNXRudnNKNDhpdU84Tmxxc202cy1DMjBkWFNqZGRRREc0MDgxeFRLZFQwcmxGN3lRdkI4bUxiQ2hLMlFhcnJJSHdEQ0V1TXc0WHhJam9MQXZ5S2RhUkRYZ3FsZW…
Immatics: PRAME Is Becoming More Than A Single-Asset Story (NASDAQ:IMTX) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNenRCSWJQTEw3cDB3ZUtBb3RLS3Nmb3Z0SEhmbTkzNHdhV1BYVWliUnhZWi1QNElhMkVBcU5xX25FUUZ6anR2TmRPdkpWN2lILWdHaHFtLUtuUHZGZGxRSFFUaDM4UHdFU09pLWJVRTJoaUpDeUpjNnFvb3o1bTdKRmlqYVVSSHZhY1ljdU…
Immatics Announces First Quarter 2026 Financial Results and Business Update - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxORTY3NV8wcTBwSWFsWFBwY2tta1l5NXdJVTlQZ1RYRW1xQURYQ2daNFFOeEM0MGp5NVlvbzl5WURBOVowTV83YUFsQWdyb1ZxbnppOFVFeGlZc3ZFSjMzQjVDYUFJQ21oTFpSMVc2MzNPa0tkOGxva3hULVMyUzJlYXNTWVJpLVUxNlN0aV…
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOTnJXZVd6aVdMR29WSUpSOW9wU2wwRzc1Q0M5dFYtZlEzbTdrdVJwWVpfa1pzcDJobzZsSEVYbXhmb2dGbTFyX05yZzJJSUN1LUpaQlZ2UzRhZUkyWnJCV1NJVFlEYmFPaFRla3FJVzZ6OWEzS2YwdExQN0ItSEFyWWw1SFNHMnF2eEYxWV…
IMTX — Frequently Asked Questions
What is the current share price of IMTX?
As of 2026-08-05 17:25 PDT, IMTX trades at $9.77 on NASDAQ/NYSE. Its 52-week range is $5.09 to $11.87.
What is the market capitalisation of IMTX?
IMTX has a market capitalisation of $1.31B on NASDAQ/NYSE.
What is the P/E ratio of IMTX?
IMTX trades at a trailing price-to-earnings (P/E) ratio of -6.07. Its price-to-book (P/B) ratio is 2.71.
What is the return on equity (ROE) of IMTX?
IMTX has a return on equity (ROE) of -40.58%. Its return on capital employed (ROCE) is -35.05%.
Is IMTX a good stock to buy?
This page provides a data-driven analysis of IMTX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.